Literature DB >> 29340562

Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015.

Alexander C Egilman1, Joshua D Wallach1, Joseph S Ross1,2, Sanket S Dhruva3.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29340562      PMCID： PMC5876838          DOI： 10.1001/jamainternmed.2017.8016

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  1 in total

1.  Estimation of Potential Savings Through Therapeutic Substitution.

Authors:  Michael E Johansen; Caroline Richardson
Journal:  JAMA Intern Med       Date:  2016-06-01       Impact factor: 21.873
  1 in total
  2 in total

1.  Trends in Use and Expenditures of Brand-name Atorvastatin After Introduction of Generic Atorvastatin.

Authors:  Haider J Warraich; Joseph A Salami; Rohan Khera; Javier Valero-Elizondo; Victor Okunrintemi; Khurram Nasir
Journal:  JAMA Intern Med       Date:  2018-05-01       Impact factor: 21.873

2.  Generic Drugs in the United States: Policies to Address Pricing and Competition.

Authors:  Ravi Gupta; Nilay D Shah; Joseph S Ross
Journal:  Clin Pharmacol Ther       Date:  2019-01-10       Impact factor: 6.875
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.